Consistent with this, it was shown that glutaminase inhibitor CB-839 suppresses tumor growth of KEAP1-mutant cell line- or patient-derived xenografts (PDXs) much more potently than that of KEAP1-WT counterparts (Romero et al., 2017; Galan-Cobo et al., 2019). Here, KEAP1 is linked to neoplasm.